Spotlight On... Dengue vaccine developed at NIH enters PhIII in Brazil; Mucosis nets Wellcome Trust grant for intranasal RSV vax; Brazil commits to Zika research; and more...

A dengue fever vaccine developed by scientists at the National Institute of Allergy and Infectious Diseases is entering a Phase III trial in Brazil that may enroll nearly 17,000 people in 13 cities. The trial is expected to last 5 years, but investigators hope for early efficacy indications in less than two years. The São Paulo-based Butanatan Institute is sponsoring the trial and has licensed the vaccine technology, dubbed TV003. More

> Dutch vaccines firm Mucosis received a €3.7 million grant from Wellcome Trust to take its intranasal RSV vaccine to Phase I/IIa trials in conjunction with Imperial College London. Release

> Indian officials are working to set up a system that will track vaccine movement, usage and availability. News

> In the midst of the largest known Zika outbreak, the Brazilian government is committing funds to help develop a vaccine. Report

> Researchers are taking a vaccine targeting non-small cell lung cancer into an 812-patient Phase III trial. The work centers on a potential new biomarker that may help boost efficacy. Report

> Inovio Pharmaceuticals ($INO) netted a $500,000 Small Business Innovation Research grant from the U.S. Army to continue work on next-gen vaccine delivery. Release

And Finally… An Oxford University team is looking into using "bacterial superglue" to speed up the vaccine development process. News

Suggested Articles

The U.K.'s two new deals with J&J and Novavax bring its stockpile of potential COVID-19 vaccines to 340 million doses while expanding clinical trials.

Just one week after inking a COVID-19 vaccine deal with the U.S. for 100 million doses, J&J reached a supply agreement twice that size with the EU.

Moderna, after tapping almost $1 billion in federal funding, agreed to deliver 100 million doses of its vaccine candidate for up to $1.5 billion.